Avacta Group PLC Avacta to Present at the Shares Spotlight Evening
April 19 2017 - 1:00AM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
19 April 2017
19 April 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to Present at the Shares Spotlight Evening
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, is pleased to announce that
its Chief Executive, Alastair Smith, will be presenting at the
Shares Spotlight Evening on Wednesday 26(th) April at the Novotel
Hotel, Tower Bridge, London, EC3N 2NR.
The evening event, which begins at 18:00, provides an
opportunity for investors to hear about the Company's Affimer(R)
technology, its development plans and to meet with management.
ENDS
NOTES
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414
Alastair Smith, Chief Executive 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0) 207 220
Geoff Nash / Giles Rolls - 0500
Nominated Adviser www.finncap.com
Tim Redfern / Alice Lane -
Corporate Broking
Tel: +44 (0) 203 705
WG Partners 9318
Nigel Birks / Nigel Barnes Tel: +44 (0) 203 705
David Wilson / Claes Spang 9217
www.wgpartners.co.uk
Zyme Communications (Trade Tel: +44 (0)7787 502
and Regional Media) 947
Katie Odgaard katie.odgaard@zymecommunications.com
FTI Consulting (Financial Tel: +44 (0) 203 727
Media and IR) 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Affimer technology has been designed to address many of the
negative performance issues of antibodies, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAXVLFFDZFEBBK
(END) Dow Jones Newswires
April 19, 2017 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024